Subclinical Optic Nerve Changes After Le Fort I Osteotomy
Evaluation of Subclinical Optic Nerve Head Changes After Le Fort I Osteotomy Using Retinal Nerve Fiber Layer Optical Coherence Tomography
Le Fort I osteotomy is a common jaw surgery that includes a step called pterygomaxillary dysjunction, during which force applied with a surgical instrument (osteotome) can be transmitted toward the eye socket (orbit) and the optic nerve canal. Serious eye complications after this surgery are rare, but it is not known whether smaller, subclinical changes occur in the optic nerve that go unnoticed without special testing. This study uses a non-invasive eye imaging test called optical coherence tomography (OCT) to measure the thickness of the nerve fiber layer around the optic nerve, before and after Le Fort I surgery, to find out whether such changes occur.
Descripción general del estudio
Estado
Estado
Condiciones
Condiciones
Intervención / Tratamiento
Intervención / Tratamiento
Descripción detallada
Fifty patients aged 18-45 years scheduled for isolated Le Fort I osteotomy or Le Fort I osteotomy combined with bilateral sagittal split osteotomy (BSSO) will be enrolled in this single-center, prospective, observational cohort study. Each patient serves as their own control (within-subject comparison across time points). All participants will undergo ophthalmologic examination, RNFL-OCT imaging, optic disc morphology assessment (disc area, elongation ratio, presence of disc head hemorrhage), and Humphrey 30-2 visual field testing at three time points: preoperatively (T0, within 1 week before surgery), 1 week postoperatively (T1), and 3 months postoperatively (T2). All ophthalmologic measurements will be performed by a single examiner blinded to intraoperative surgical details, using the same device throughout. Maxillary advancement amount and pterygomaxillary junction depth/concavity angle will be measured preoperatively on CBCT (pterygomaxillary junction measured bilaterally, with Observer 1 measuring twice for intraobserver reliability and Observer 2 measuring once for interobserver reliability). No intervention, randomization, or treatment-group allocation occurs as part of this study; all participants receive their routine, already-planned orthognathic surgical care. A priori power analysis (G*Power, RM ANOVA within-between interaction, f=0.25, epsilon=1, alpha=0.05, power=0.90) indicated a minimum required sample size of N=36; n=50 was set to allow for attrition.
Tipo de estudio
Tipo de estudio
Inscripción (Estimado)
Inscripción
Contactos y Ubicaciones
Estudio Contacto
Estudio Contacto
- Nombre: Yağmur M Okumuş, Assistant Professor, DDS, Phd
- Número de teléfono: +90 5304054615
- Correo electrónico: yagmur.malkoc@medipol.edu.tr
Criterios de participación
Criterio de elegibilidad
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Método de muestreo
Población de estudio
Adult patients aged 18-45 years scheduled for isolated Le Fort I osteotomy or Le Fort I combined with bilateral sagittal split osteotomy (BSSO) at Istanbul Medipol University, with no pre-existing ocular or orbital pathology that could independently affect retinal nerve fiber layer thickness or optic disc morphology.'
Descripción
Inclusion Criteria:
Aged 18-45 years, able to provide written informed consent. Isolated Le Fort I osteotomy or Le Fort I + BSSO (bilateral sagittal split osteotomy) planned.
ASA Physical Status Classification I-II. Standard osteotome technique used for pterygomaxillary dysjunction. Sufficient ocular media clarity to permit OCT imaging.
Exclusion Criteria:
Known glaucoma, optic neuropathy, retinal disease, or other ocular pathology affecting the retinal nerve fiber layer.
Prior ocular/orbital surgery or trauma. Craniofacial syndrome (e.g., cleft lip/palate). Segmental Le Fort osteotomy or revision orthognathic surgery. Unwilling or unable to provide informed consent.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Modelos observacionales: COHORT
- Perspectivas temporales: OTHER
Número de grupos/cohortes
Cohortes e Intervenciones
Grupo / CohorteGrupo / Cohorte |
Intervención / TratamientoIntervención / Tratamiento |
|---|---|
|
Le Fort I osteotomy cohort
Patients undergoing isolated Le Fort I osteotomy or Le Fort I combined with bilateral sagittal split osteotomy (BSSO). No randomization or treatment allocation; all participants receive their routine, already-planned orthognathic surgical care. Diagnostic Test: RNFL-OCT and optic disc morphology assessment (disc area, elongation ratio, disc head hemorrhage), performed preoperatively (T0) and at 1 week (T1) and 3 months (T2) postoperatively. Diagnostic Test: Humphrey 30-2 visual field testing, performed at the same three time points. Diagnostic Test: Preoperative CBCT measurement of pterygomaxillary junction depth and concavity angle, and maxillary advancement amount from surgical planning data. |
Peripapillary retinal nerve fiber layer thickness and optic disc morphology (disc area, elongation ratio, presence of disc head hemorrhage) measured by optical coherence tomography, performed preoperatively (T0) and at 1 week (T1) and 3 months (T2) postoperatively. Humphrey 30-2 Visual Field Testing Açıklama: Standard automated perimetry (Humphrey 30-2 program) performed at the same three time points (T0, T1, T2) to assess mean deviation and pattern standard deviation. Cone-beam computed tomography measurement of pterygomaxillary junction depth and concavity angle, and maxillary advancement amount from virtual surgical planning data, obtained preoperatively. |
¿Qué mide el estudio?
Medidas de resultado primarias
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Change in Peripapillary Retinal Nerve Fiber Layer (RNFL) Thickness
Periodo de tiempo: Baseline (T0, preoperative) to 3 months (T2) postoperatively
|
Change in peripapillary retinal nerve fiber layer (RNFL) thickness, measured by optical coherence tomography (OCT), from baseline (T0, preoperative) to 1 week (T1) and 3 months (T2) after Le Fort I osteotomy. |
Baseline (T0, preoperative) to 3 months (T2) postoperatively
|
Medidas de resultado secundarias
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Change in Optic Disc Area and Elongation Ratio
Periodo de tiempo: Baseline (T0) to 3 months (T2) postoperatively
|
Change in optic disc area and elongation ratio (vertical/horizontal), measured by OCT, from baseline (T0) to 1 week (T1) and 3 months (T2) after Le Fort I osteotomy. |
Baseline (T0) to 3 months (T2) postoperatively
|
Colaboradores e Investigadores
Patrocinador
Patrocinador
Investigadores
Investigadores
- Director de estudio: Sina Uçkan, prof., Medipol University
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Estimado)
Inicio del estudio
Finalización primaria (Estimado)
Finalización primaria
Finalización del estudio (Estimado)
Finalización del estudio
Fechas de registro del estudio
Enviado por primera vez
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Publicado por primera vez
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización publicada
Última actualización enviada que cumplió con los criterios de control de calidad
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
Otros números de identificación del estudio
- IstanbulMUH-DF-YM-03
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .